Ginkgo Bioworks Holdings, Inc.
DNAGinkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company that specializes in organism engineering and synthetic biology. By designing and programming custom microbes, Ginkgo aims to develop sustainable solutions across industries such as agriculture, pharmaceuticals, food, and specialty chemicals. The firm leverages automation, data, and engineering to accelerate biological research and product development.
Company News
Palantir and Ginkgo Bioworks are positioned on opposite sides of an emerging biosecurity debate. Palantir represents the intelligence layer for threat identification, while Ginkgo represents the biological infrastructure layer for faster biological responses. The article explores whether future value will come from identifying threats first or bu...
The point-of-care diagnostics market has reached $58.76 billion globally in 2026, growing at nearly 10% annually, with projections to reach $114.65 billion by 2035. Five companies are leading this structural shift toward decentralized, consumer-facing healthcare: VentriPoint Diagnostics is expanding globally with AI-powered cardiac imaging; Hims ...
ProQR Therapeutics announced pipeline expansion with multiple clinical programs advancing toward the clinic. The company's lead program AX-0810 is on track to report target engagement data in H1 2026, with biliary atresia selected as the initial Phase 2 indication. Additional programs AX-0811, AX-0422, and AX-2911 are progressing with anticipated...
A-Alpha Bio, a biotechnology company using synthetic biology and machine learning, has hired Troy Lionberger as Chief Business Officer to lead business development and expand partnerships across biopharma and adjacent sectors.
The microbial fermentation technology market is experiencing significant growth, driven by the increasing incidence of chronic diseases and the growing demand for cutting-edge treatments. North America is expected to dominate the market during the forecast period.
